{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:47Z","timestamp":1762865807862},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.blre.2011.02.001","type":"journal-article","created":{"date-parts":[[2011,4,2]],"date-time":"2011-04-02T04:54:22Z","timestamp":1301720062000},"page":"139-146","source":"Crossref","is-referenced-by-count":16,"title":["Interpretation of cytogenetic and molecular results in patients treated for CML"],"prefix":"10.1016","volume":"25","author":[{"given":"Carlos E.","family":"Vigil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Wetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.02.001_bb0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","author":"Deininger","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2011.02.001_bb0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr\u2013abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0020","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.02.001_bb0025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"author":"National Comprehensive Cancer Network","key":"10.1016\/j.blre.2011.02.001_bb0035"},{"issue":"Suppl 2","key":"10.1016\/j.blre.2011.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190903370387","article-title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","volume":"50","author":"Aguayo","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.02.001_bb0045","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2011.02.001_bb0050","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4065\/80.3.390","article-title":"Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2011.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR\u2013ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0065","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jcla.20008","article-title":"A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination","volume":"18","author":"Riley","year":"2004","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.blre.2011.02.001_bb0075","first-page":"295","article-title":"Cytogenetic and fluorescence in situ hybridization monitoring in Ph+chronic myeloid leukemia patients treated with imatinib mesylate","volume":"23","author":"Fugazza","year":"2004","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.02.001_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-4608(02)00558-7","article-title":"Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia","volume":"137","author":"Lesser","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.blre.2011.02.001_bb0085","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR\u2013ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.02.001_bb0090","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.02.001_bb0100","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.02.001_bb0105","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0110","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0115","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0120","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.02.001_bb0125","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR\u2013ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR\u2013ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0135","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0140","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.02.001_bb0145","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.02.001_bb0150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1185\/03007990903479299","article-title":"Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study","volume":"26","author":"Michallet","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2011.02.001_bb0155","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.02.001_bb0160","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.02.001_bb0165","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.02.001_bb0170","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0175","article-title":"Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily","volume":"28","author":"Shah","year":"2009","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.02.001_bb0180","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr\u2013Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.02.001_bb0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.02.001_bb0190","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study","volume":"27","author":"Kantarjian","year":"2009","journal-title":"ASCO Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.02.001_bb0195","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR\u2013ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.02.001_bb0200","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T15:24:07Z","timestamp":1543850647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0268960X11000191"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.02.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"type":"print","value":"0268-960X"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}